Bearish flow noted in Apellis Pharmaceuticals with 4,906 puts trading, or 5x expected. Most active are 11/10 weekly 31 puts and 11/10 weekly 44 puts, with total volume in those strikes near 3,200 contracts. The Put/Call Ratio is 3.96, while ATM IV is up nearly 11 points on the day. Earnings are expected on February 20th.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 3 Years in Patients with Geographic Atrophy (GA)
- Apellis price target raised to $86 from $70 at Baird
- Apellis initiated with a Neutral at Mizuho
- Apellis price target raised to $63 from $60 at Needham
- Apellis reports Q3 EPS ($1.17), consensus (85c)